The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Perusini MA et al. Leukemia, May 2026

• Share
• Tweet
• Share
• Share